Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women

Black, D. M.; Schwartz, A. V.; Ensrud, K. E.
May 2007
ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p64
Academic Journal
The article presents a study on the effects of the continuing alendronate treatment for 5 years on postmenopausal women with low bone mineral density (BMD). Results revealed that 5 additional years of alendronate maintained total hip BMD compared to a decrease with placebo. It also indicated that continuing alendronate treatment led to fewer clinical vertebral fractures. It is concluded that postmenopausal women with low BMD who continued treatment for 5 years maintained BMD.


Related Articles

  • Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women: COMMENTARY. Baillie, Cory // ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p64 

    The author comments on a study on the effect of continuing alendronate treatment for 5 years in postmenopausal women with low bone mineral density (BMD). He asserted that the results of the trial may be the best data that clinicians have to investigate to answer the appropriate duration of...

  • Ibandronate Injection.  // AHFS Consumer Medication Information;Sep2016, p1 

    Ibandronate injection is used to treat osteoporosis (a condition in which the bones become thin and weak and break easily) in women who have undergone menopause (''change of life;'' end of menstrual periods). Ibandronate is in a class of medications called bisphosphonates. It works by preventing...

  • disodium etidronate.  // Royal Society of Medicine: Medicines;2002, p208 

    This article presents information on disodium etidronate which is a biphosphonate used to treat disorders of bone metabolism due to disorders. It is also available in a compound preparation with calcium carbonate to prevent or treat osteoporosis in post-menopausal women. Its administration is...

  • Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Flood, Emuella M.; Beusterien, Kathleen M.; Green, Hannah; Shikiar, Richard; Baran, Robert W.; Amonkar, Mayur M.; Cella, David // Health & Quality of Life Outcomes;2006, Vol. 4, p42 

    Background: The Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) is a new measure of patient satisfaction with bisphosphonate treatment for osteoporosis. The objective of this study was to evaluate the psychometric characteristics of the OPSAT-Q. Methods: The OPSAT-Q contains 16 items...

  • Alendronate may help prevent steroid-induced osteoporosis in women.  // Geriatrics;Sep98, Vol. 53 Issue 9, p16 

    Focuses on a study conducted in the United States which reported that bisphosponate alendronate sodium (Fosomax) can prevent and treat postmenopausal osteoporosis and osteoporosis caused by corticosteroid therapy in women. Comments from study co-author, Kenneth Saag; Information on...

  • Long-Term Safety of Bisphosphonate Therapy for Osteoporosis: A Review of the Evidence. Liberman, Uri A. // Drugs & Aging;2006, Vol. 23 Issue 4, p289 

    This article reviews the long-term safety profile of bisphosphonates for the treatment and prevention of osteoporosis in postmenopausal women. Bisphosphonates inhibit osteoclastic resorption and reduce the rate of bone turnover, thereby reducing fracture risk. Placebo-controlled trials of oral...

  • Bisphosphonates reduce costs--if women take them.  // Contemporary OB/GYN;Nov2006, Vol. 51 Issue 11, p29 

    The article discusses research being done on the influence of bisphosphonates administration on the health care costs associated with osteoporosis care in menopausal women. It references a study by J. Curtis and colleagues, presented at the 17th annual meeting of the North American Menopause...

  • Bisphosphonate drug holidays: Can we recommend currently? Tandon, Vishal R.; Sharma, Sudhaa; Mahajan, Annil // Journal of Mid-life Health;Jul-Sep2014, Vol. 5 Issue 3, p111 

    Bisphosphonates (BP) are the mainstay of treatment for osteoporosis. Subtrochanteric or diaphyseal fractures have been reported with long term use of BP, which raised world-wide debate on two aspects, i.e., for how long the BP is to be given and potential advantages/role of BP drug holidays. BP...

  • Osteoporosis: targeting those at risk. Stevenson, John C // Journal of the British Menopause Society;2000 Supplement, Vol. 6, p19 

    The article discusses the management of osteoporosis and fractures. The risk of osteoporosis increases with age due to a diminishing bone density. Osteoporotic fractures can be prevented by treatments, including hormone replacement therapy (HRT), bisphosphonates, calcium and vitamin D. HRT has...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics